$5.88
+0.06(1.03%)
Mkt Cap $50M
$3.77
$10.09
52-Week Range
At a Glance
AI-generatedKaryopharm Therapeutics Inc.
Revenue breakdown: Product (73.2%), License And Other (21%), Royalty (2.9%).
8-K
Karyopharm Therapeutics Inc. entered into a private placement with RA Capital Management on March 24, 2026, issuing securities for gross proceeds of approximately $30 million, and separately sold shares under an existing market agreement for net proceeds of approximately $19.8 million. The company stated its existing liquidity, including these proceeds, is expected to fund its current operating plans into late in the third quarter of 2026.$50M
Market Cap
$69M
Revenue
-$93M
Net Income
Employees279
Fundamentals
How The Business Makes Money
Revenue by Segment
Product73.2%($340M)
License And Other21%($98M)
Royalty2.9%($14M)
License1.5%($7M)
License And Service1.4%($6M)
Activity
What Changed Recently
Analyst View
Company Profile
CIK0001503802
ISINUS48576U2050
CUSIP48576U205
Phone617 658 0600
Address85 Wells Avenue, Newton, MA, 02459, US
SEC EDGAR